Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Results

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.06%

Catalyst Pharmaceuticals reported a strong earnings per share, significantly beating expectations. However, the stock fell by 1.06% following the report, likely due to the lack of revenue guidance and uncertainty about future performance. Investors may be cautious as the company did not provide specific forecasts for upcoming quarters.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.70	N/A	+41.99%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting a strong performance. However, they did not offer specific guidance for future revenue.

We are pleased with our EPS performance this quarter.

While we did not provide revenue guidance, we remain focused on our long-term strategy.

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.06%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.06%

Key numbers

Management commentary